| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ligand Pharmaceuticals Inc (LGND) has 11 insiders with recent SEC Form 4 filings, including 0 buys and 17 sells. LGND is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 161.3K | $35.72M | - | |
| Dir | 44.0K | $9.74M | - | |
| Dir | 33.8K | $7.48M | - | |
| Dir | 32.8K | $7.25M | - | |
| Other | 30.8K | $6.82M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 12, 2017 | Aryeh Jason | Director | Sell | 37,247 | $110.76 | $4,125,358.41 | -13.1% | |
| Mar 20, 2017 | Higgins John L66 | Chief Executive Officer | Sell | 4,000 | $109.10 | $436,400.00 | -2.8% | |
| Mar 8, 2017 | Higgins John L66 | Chief Executive Officer | Sale+OE | 4,000 | $107.06 | $428,240.00 | -3.0% | |
| Mar 2, 2017 | Foehr Matthew W72 | President And COO | Sale+OE | 6,879 | $103.39 | $711,213.62 | -7.0% | |
| Feb 28, 2017 | Aryeh Jason | Director | Sell | 32,000 | $106.35 | $3,403,060.00 | -9.2% | |
| Nov 25, 2016 | Aryeh Jason | Director | Sell | 18,479 | $107.31 | $1,983,072.28 | -4.7% | |
| Nov 18, 2016 | Aryeh Jason | Director | Sell | 6,330 | $105.28 | $666,418.90 | -1.5% | |
| Sep 22, 2016 | Higgins John L66 | Chief Executive Officer | Sell | 3,000 | $117.34 | $352,020.00 | -2.4% | |
| Sep 7, 2016 | Kozarich John W61 | Director | Sell | 1,000 | $115.00 | $115,000.00 | -2.4% | |
| Sep 1, 2016 | Kozarich John W61 | Director | Sell | 1,666 | $105.40 | $175,596.80 | -1.0% |